P1701Randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China

作者：Junbao Du, Chenfei Rao, Z. Zheng, MISSION Collaborative Group · 发表于：European Heart Journal · 年份：2018 · DOI：10.1093/eurheartj/ehy565.p1701 · 被引用次数：6 · 研究领域：Health Systems, Economic Evaluations, Quality of Life、Medication Adherence and Compliance、Pharmaceutical Economics and Policy

Background: The benefits of secondary preventive drugs after coronary artery bypass grafting have been thoroughly established. However, the prescription rates of these drugs are low at discharge in China. Objectives: We sought to evaluate the effectiveness of continuous quality improvement with mobile-based interventions for clinicians on improving the guideline-adherence of secondary preventive drugs prescription. Methods: MISSION-1 study is a cluster-randomized controlled trial. Hospitals participating in the China cardiac surgery registry were invited and randomly into the intervention group or the control group in a 1:1 ratio. The intervention group undertakes a series of mobile-based interventions, while the control group maintains a routine practice pattern. All sites consecutively register patients underwent isolated CABG and submit in-hospital data. We require supporting documents regarding prescription information at discharge to adjudicate the outcome measures. The primary outcome measure is the prescription rate of statins for eligible patients at discharge. The secondary outcome measures are antiplatelet drugs, β-blockers and AECIs or ARBs.